Trial results for a real-world study investigating the efficacy of Tofacitinib and Tumor Necrosis Factor Inhibitors (TNFi) in Rheumatoid Arthritis were posted on ClinicalTrials.gov on 2025-12-23, with 9159 participants enrolled.
Background
Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the joints, leading to pain, swelling, stiffness, and potential joint damage. Current treatment strategies often involve disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs like methotrexate (MTX), and biologic DMARDs such as Tumor Necrosis Factor Inhibitors (TNFi). Tofacitinib, an oral Janus kinase (JAK) inhibitor, represents another class of targeted therapies. Understanding the real-world efficacy of these treatments, both as monotherapy and in combination, is crucial for optimizing patient care and treatment guidelines. This study provides insights into how these therapies perform in routine clinical practice.
Trial design
This completed study, which did not specify a phase, enrolled 9159 participants with Rheumatoid Arthritis. The trial aimed to estimate the efficacy of treatment with TNFi as monotherapy or in combination therapy with MTX, and to compare and contrast this efficacy with Tofacitinib as monotherapy and in combination therapy, all within a real-world setting.
Key results
The trial reported several key measurements related to the Clinical Disease Activity Index (CDAI) score at 6 months for various treatment groups:
- CDAI Score at 6 Months for Tofacitinib Monotherapy vs Tofacitinib With Methotrexate (MTX):
- For Tofacitinib Initiators Combination, the mean CDAI score was 18.1 (Standard Deviation 15.1 units).
- For Tofacitinib Initiators Monotherapy, the mean CDAI score was 17 (Standard Deviation 13.4 units).
- In another measurement for Tofacitinib Initiators Combination, the mean CDAI score was 16.6 (Standard Deviation 14.3 units).
- For Tofacitinib Initiators Monotherapy, the mean CDAI score was 14.6 (Standard Deviation 11.6 units).
- CDAI Score at 6 Months for Tumor Necrosis Factor Inhibitor (TNFi) Monotherapy vs TNFi Combination With MTX:
- For All TNFi Initiators Combination, the mean CDAI score was 13.9 (Standard Deviation 12.5 units).
- For All TNFi Initiators Monotherapy, the mean CDAI score was 16.5 (Standard Deviation 13.8 units).
- In another measurement for All TNFi Initiators Combination, the mean CDAI score was 13 (Standard Deviation 11.8 units).
- For All TNFi Initiators Monotherapy, the mean CDAI score was 14.9 (Standard Deviation 13 units).
- CDAI Score at 6 Months for Tofacitinib Monotherapy vs TNFi Combination With MTX:
- For All TNFi Initiators Combination, the mean CDAI score was 13.9 (Standard Deviation 12.5 units).
- For Tofacitinib Initiators Monotherapy, the mean CDAI score was 17 (Standard Deviation 13.4 units).
- In another measurement for All TNFi Initiators Combination, the mean CDAI score was 13 (Standard Deviation 11.8 units).
- For Tofacitinib Initiators Monotherapy, the mean CDAI score was 14.6 (Standard Deviation 11.6 units).
Key analyses using mixed model linear regression reported p-values of 0.278, 0.131, and 0.987.
What this means
The real-world data from this large study provides comparative insights into the efficacy of Tofacitinib and TNFi therapies for Rheumatoid Arthritis, both as monotherapy and in combination with MTX, as measured by CDAI scores at 6 months. Generally, combination therapies tended to show lower (indicating better disease activity) mean CDAI scores compared to monotherapies for both Tofacitinib and TNFi. Specifically, the lowest mean CDAI scores were observed in the TNFi combination groups. The reported p-values from mixed model linear regression (0.278, 0.131, 0.987) suggest that the observed differences in some comparisons may not have reached statistical significance. These findings contribute to the understanding of treatment effectiveness in a real-world clinical setting, which can inform treatment decisions and future research into optimal RA management strategies.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT05576051, titled "To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.", were posted on 2025-12-23 on clinicaltrials.gov.